Kerri Fitzgerald

DocwireNews

Researchers found that the stage at which diffuse large B-cell <a href="https://www.docwirenews.com/conference-coverage/soho/inflammatory-and-immune-manifestations-in-patients-with-chronic-myelomonocytic-leukemia/">lymphoma</a> (DLBCL) is diagnosed can impact the types of secondary cancers that form after treatment.The study assessed outcomes in 26,038 patients diagnosed with DLBCL between 1973 and 2010. More than half of patients were diagnosed with stage I or II disease. Overall, 13% of survivors developed a second primary cancer.&ldquo;We&rsquo;ve known that, genetically, early and late stage disease is different, and our hypothesis was that the type and timing of <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/together-two-genetic-mutations-make-blood-cancer-more-aggressive/">secondary primary cancers</a> may thus be different as well,&rdquo; said Manali Kamdar, MD, of the University of Colorado Cancer Center and clinical director of lymphoma services at UCHealth University of Colorado Hospital, in a press release.<h2>Type and timing of secondary cancer differ</h2>Patients diagnosed with early-stage DLBCL had a higher risk of developing second primary cancers in the five years following treatment, most of which were solid tumors in the breast, colon, or prostate. However, patients diagnosed with stage III or IV DLBCL had an increased risk of developing second primary cancers in the 10 to 15 years after treatment; most of these cancers were hematologic malignancies.&ldquo;This is a first step toward identifying tools in survivorship clinics to better surveil survivors. It benefits patients because we may be able to better identify risk,&rdquo; said Dr. Kamdar.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Lymphoma Stage at Diagnosis May Predict Site of Secondary Malignancy

Oncology

Researchers found that the stage at which diffuse large B-cell lymphoma (DLBCL) is diagnosed can impact the types of secondary cancers that form after treatment. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe